
NASH and NAFLD are notoriously difficult to treat conditions.
Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.

NASH and NAFLD are notoriously difficult to treat conditions.

The schizophrenia drug currently has a PDUFA date set for November 15.

The Arbor Pharmaceutical drug is aimed at treating ADHD without being manipulated for non-oral use.

The investigators also found the effects of dapagliflozin were similar in patients with type 2 diabetes and those without type 2 diabetes.

There was also a decline depression care in recent years among adolescents and young adults.

A virtual reality platform could enable ADHD patients to improve cognitive functioning.

Experts expect an increase in mental health issues caused by the pandemic in the future.

The Digihaler is a digital inhaler aimed at improving inhaler techniques.

Medication might be best used as a first-line option for patients with ADHD.

Researchers suggest avoiding cow’s milk formula for newborns in the first 3 days of life.

Nephrologists have used telemedicine tools to help treat patients during the pandemic.

Patients who received the combination of nivolumab and ipilimumab survived a median of 18.1 months, while patients who underwent chemotherapy survived a median of 14.1 months.

Dr. Moon says new strategies must be implemented to help NAFLD patients deal with pain.

The risk of VTE is increased in both hospitalized and non-hospitalized COVID-19 patients.

This edition from the 10 Year Plan features perspective from leadership at WGO and Crohn's & Colitis Foundation, as well as survey results from gastroenterologists.

There could be a lasting impact caused by some of the changes due to the pandemic.

This edition from the 10 Year Plan features perspective from leadership at APA and AADPRT, as well as survey results from psychiatrists.

SFChT in treatment-naïve eyes was positively associated with eGFR and diabetic retinopathy grade.

A high proportion of end-stage kidney disease patients have suffered severe COVID-19 outcomes.

The orphan drug will be the first ever FDA-approved granular hydrocortisone formulation specifically developed for pediatric patients.

As part of the TARGET-NASH study, researchers find 18% of NAFLD patients are prescribed opioids because of pain.

For many patients suffering from depression or anxiety, the added stress of the pandemic has led to a medication change.

There was a high proportion of RSV-associated acute lower respiratory infections hospitalizations in infants younger than 1 in all countries.

Because ADHD presents differently in females than it does in males, the disorder has been underdiagnosed in females for several years.

Mepolizumab will be used to treat both adult and pediatric patients with HES for at least 6 months without an identifiable non-hematologic secondary cause.

The treatment could also be used for Alzheimer disease and mid-stage Huntington disease for patients who suffer from greater cognitive deficits.

For obese patients, both weight gain and loss was linked to an increase in the rate of incident venous thromboembolism.

Dr. Yuen discusses some new treatments in the pipeline and how personalized medicine could make an impact in HBV treatment.

The trial was called off because of futility of the toxoid vaccine candidate.

The highest suPAR tertile was linked to a 9.15-fold increase in the odds of an acute kidney injury.